ORs and GREs for colorectal cancer risk according to the healthy lifestyle score in subgroups by cancer site and stage
| CRC | Healthy lifestyle score | Cases, n (%) | Controls, n (%) | OR (95% CI)1 | GRE (95% CI) |
|---|---|---|---|---|---|
| Colon cancer | 0–2 | 885 (30.2) | 876 (22.2) | Ref. | Ref. |
| 3 | 1,060 (36.2) | 1,337 (33.9) | 0.79 (0.69, 0.91) | −19.3 (−30.7, −7.8) | |
| 4 | 770 (26.3) | 1,175 (29.8) | 0.63 (0.55, 0.73) | −37.8 (−51.1, −24.6) | |
| 5 | 217 (7.4) | 553 (14.0) | 0.39 (0.32, 0.47) | −77.0 (−97.3, −56.8) | |
| Per 1-point increase | 0.78 (0.74, 0.82) | −20.3 (−25.5, −15.1) | |||
| Rectal cancer | 0–2 | 634 (33.7) | 876 (22.2) | Ref. | Ref. |
| 3 | 655 (34.8) | 1,337 (33.9) | 0.75 (0.64, 0.88) | −22.0 (−34.7, −9.2) | |
| 4 | 463 (24.6) | 1,175 (29.8) | 0.61 (0.51, 0.73) | −37.7 (−52.5, −23.0) | |
| 5 | 130 (6.9) | 553 (14.0) | 0.37 (0.29, 0.48) | −75.9 (−98.7, −53.0) | |
| Per 1-point increase | 0.77 (0.73, 0.82) | −19.9 (−25.7, −14.2) | |||
| P value for heterogeneity between strata (3/4/5 points) = 0.41/0.57/0.83 | |||||
| CRC (stage I) | 0–2 | 309 (28.0) | 876 (22.2) | Ref. | Ref. |
| 3 | 401 (36.3) | 1,337 (33.9) | 0.87 (0.72, 1.04) | −11.4 (−26.5, 3.7) | |
| 4 | 303 (27.4) | 1,175 (29.8) | 0.76 (0.62, 0.92) | −22.5 (−39.3, −5.6) | |
| 5 | 92 (8.3) | 553 (14.0) | 0.49 (0.37, 0.64) | −58.4 (−84.0, −32.7) | |
| Per 1-point increase | 0.84 (0.79, 0.90) | −14.3 (−20.7, −7.9) | |||
| CRC (stage II) | 0–2 | 501 (34.1) | 876 (22.2) | Ref. | Ref. |
| 3 | 548 (37.3) | 1,337 (33.9) | 0.74 (0.62, 0.87) | −24.6 (−39.0, −10.3) | |
| 4 | 324 (22.1) | 1,175 (29.8) | 0.47 (0.39, 0.57) | −61.8 (−81.2, −42.4) | |
| 5 | 96 (6.5) | 553 (14.0) | 0.32 (0.24, 0.42) | −93.2 (−121.7, −64.8) | |
| Per 1-point increase | 0.71 (0.67, 0.76) | −28.0 (−35.6, −20.4) | |||
| CRC (stage III) | 0–2 | 464 (30.6) | 876 (22.2) | Ref. | Ref. |
| 3 | 505 (33.3) | 1,337 (33.9) | 0.74 (0.63, 0.88) | −24.6 (−39.1, −10.1) | |
| 4 | 423 (27.9) | 1,175 (29.8) | 0.67 (0.56, 0.80) | −32.8 (−48.7, −16.9) | |
| 5 | 124 (8.2) | 553 (14.0) | 0.43 (0.33, 0.55) | −69.1 (−93.3, −44.8) | |
| Per 1-point increase | 0.81 (0.76, 0.86) | −17.2 (−23.4, −11.1) | |||
| CRC (stage IV) | 0–2 | 234 (34.4) | 876 (22.2) | Ref. | Ref. |
| 3 | 244 (35.8) | 1,337 (33.9) | 0.77 (0.62, 0.96) | −21.4 (−40.1, −2.6) | |
| 4 | 170 (25.0) | 1,175 (29.8) | 0.60 (0.47, 0.76) | −41.8 (−64.6, −19.0) | |
| 5 | 33 (4.8) | 553 (14.0) | 0.25 (0.16, 0.37) | −113.4 (−157.8, −69.0) | |
| Per 1-point increase | 0.72 (0.66, 0.79) | −26.9 (−36.8, −17.0) | |||
| P value for heterogeneity between strata (3/4/5 points) = 0.23/0.00015/0.0018 | |||||
1Variables in the model included age, gender, school education, family history of CRC, history of colonoscopy, participation in routine health check-ups, use of nonsteroidal anti-inflammatory drugs, healthy lifestyle score, and PRS (per 10 percentiles, continuous). CI, confidence intervals; CRC, colorectal cancer; GRE, genetic risk equivalent; OR, odds ratio; PRS, polygenic risk score; Ref., reference.